Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy.

Lønning PE, Taylor PD, Anker G, Iddon J, Wie L, Jørgensen LM, Mella O, Howell A.

Breast Cancer Res Treat. 2001 May;67(2):111-6.

PMID:
11519859
2.

High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.

Mahtani RL, Stein A, Vogel CL.

Clin Ther. 2009;31 Pt 2:2371-8. doi: 10.1016/j.clinthera.2009.11.002.

PMID:
20110046
3.

Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.

Mlineritsch B, Psenak O, Mayer P, Moik M, Namberger K, Hauser-Kronberger C, Greil R.

Breast Cancer Res Treat. 2007 Nov;106(1):105-12. Epub 2007 Feb 13.

PMID:
17295045
4.

Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.

Catania C, Ascione G, Adamoli L, De Pas T, Medici M, Franceschelli L, Verri E, Magni E, Sanna G, Torrisi R, Goldhirsch A, Nolè F.

Breast Cancer Res Treat. 2007 Nov;106(1):97-103. Epub 2007 Jan 27.

PMID:
17260095
5.

High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.

Kvinnsland S, Anker G, Dirix LY, Bonneterre J, Prove AM, Wilking N, Lobelle JP, Mariani O, di Salle E, Polli A, Massimini G.

Eur J Cancer. 2000 May;36(8):976-82.

PMID:
10885600
6.
7.

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.

Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M; Arimidex Writing Committee; Investigators Committee Members.

Cancer. 2001 Nov 1;92(9):2247-58.

PMID:
11745278
8.

Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer.

Arpino G, Nair Krishnan M, Doval Dinesh C, Bardou VJ, Clark GM, Elledge RM.

Ann Oncol. 2003 Feb;14(2):233-41.

9.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
10.

Estrogen as therapy for breast cancer.

Ingle JN.

Breast Cancer Res. 2002;4(4):133-6. Epub 2002 May 15.

11.

Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.

Mathew J, Agrawal A, Asgeirsson KS, Buhari SA, Jackson LR, Cheung KL, Robertson JF.

Breast Cancer Res Treat. 2009 Jan;113(2):403-7. doi: 10.1007/s10549-008-9930-7. Epub 2008 Mar 2.

PMID:
18311583
12.

Efficacy of letrozole for advanced breast cancer in postmenopausal patients.

Ansari TN, Mahmood A, Hussain I, Samad A.

J Coll Physicians Surg Pak. 2005 Apr;15(4):204-6.

PMID:
15857590
13.

[Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].

Novoa Vargas A, Font López KC, Amador DD.

Ginecol Obstet Mex. 2011 Sep;79(9):553-7. Spanish.

PMID:
21966856
14.

Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.

Krainick-Strobel UE, Lichtenegger W, Wallwiener D, Tulusan AH, Jänicke F, Bastert G, Kiesel L, Wackwitz B, Paepke S.

BMC Cancer. 2008 Feb 26;8:62. doi: 10.1186/1471-2407-8-62.

15.

Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study.

Paridaens R, Thomas J, Wildiers J, Vermeiren P, Lobelle JP, di Salle E, Ornati G, Zurlo MG, Polli A, Lanzalone S, de Belder K.

Anticancer Drugs. 1998 Sep;9(8):675-83.

PMID:
9823425
16.

[Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer].

Yamamoto Y, Kawazoe T, Iwase H.

Gan To Kagaku Ryoho. 2005 Oct;32(10):1415-9. Japanese.

PMID:
16227740
17.

Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.

Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P, Cooper B, Honig S, Polli A, Whaley F, di Salle E, Tiffany J, Consonni A, Miller L.

J Clin Oncol. 1999 Nov;17(11):3418-25.

PMID:
10550136
18.
19.

The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast.

Paone JF, Abeloff MD, Ettinger DS, Arnold EA, Baker RR.

Surg Gynecol Obstet. 1981 Jan;152(1):70-4.

PMID:
7455895
20.

Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens.

Cohen I, Altaras MM, Beyth Y, Shapira J, Figer A, Tepper R, Cordoba M, Yigal D, Bernheim J.

Gynecol Oncol. 1997 Apr;65(1):83-8.

PMID:
9103396
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk